We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda’s Dengue Vaccine Demonstrates Long-Term Promise and Safety in Pivotal Trial
Takeda’s Dengue Vaccine Demonstrates Long-Term Promise and Safety in Pivotal Trial
Takeda Pharmaceutical’s dengue vaccine candidate, TAK-003, offered strong continued protection against dengue fever, especially infection requiring hospitalization, for up to three years with no significant safety risks, according to a late-stage study.